{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:15:45Z","timestamp":1774880145763,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by its aggressive nature and heterogeneity. This study analyzes recent trends in DLBCL including trends in hospitalization, inpatient mortality, and costs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Using the Nationwide Inpatient Sample (NIS) database from 2016 until 2020, a retrospective cohort study was performed to identify DLBCL hospitalization, discharges, and investigate outcomes. Trends were adjusted for age, sex, race, insurance type, mean household income, and hospital characteristics. Multivariable logistic regression has been used to analyze the data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 103,588,729 records were analyzed, identifying 47,425 cases with a diagnosis of DLBCL. From 2016 to 2020, hospitalizations have increased from 14,980 to 16,565. The mean age at diagnosis was 65 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Males were slightly more affected than females (57.3 vs 42.6), with an increasing trend in males from 53.7% to 62.3% (<jats:italic>P<\/jats:italic>\u2009=\u20090.03). The highest prevalence was observed in the White population, followed by Hispanics and African Americans. Notably, the prevalence among Hispanics increased from 10 to 12%, while there is a decreasing trend in other demographics (<jats:italic>P<\/jats:italic>\u2009=\u20090.05). Medicare was the most common insurance, with increasing trends, followed by Medicaid and private insurance (<jats:italic>P<\/jats:italic>\u2009=\u20090.6). Inpatient mortality increased from 6.1 to 7.1 (2016 to 2018) and decreased to 6.1% (2018 to 2020) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The mean length of the stay remained stable at 11.8\u00a0days. However, hospital charges increased from $176,131 to $212,324. Comorbidities such as obesity, hypertension, other associated lymphomas, peripheral vascular diseases, and diabetes showed an increasing trend (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Discharges to home and skilled nursing facility (SNF) decreased, while there was an increase in discharges to home with home health (HH) care and short-term care (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Risk factors for DLBCL include white male sex, with the mean age of 65\u00a0years. The incidence among the Hispanic population has been increasing over the years. There are disparities in incidence and survival among different ethnic\/demographic groups that need to be addressed by identifying targeted interventions and equitable healthcare access.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12094-025-03859-4","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:02:19Z","timestamp":1739836939000},"page":"3432-3438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diffuse large B-cell lymphoma: examining evolving patterns in mortality, incidence, and demographics"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-7609","authenticated-orcid":false,"given":"Silpa","family":"Choday","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"3","key":"3859_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.pathol.2020.12.003","volume":"53","author":"F Harrington","year":"2021","unstructured":"Harrington F, Greenslade M, Talaulikar D, Corboy G. Genomic characterisation of diffuse large B-cell lymphoma. Pathology. 2021;53(3):367\u201376.","journal-title":"Pathology"},{"issue":"1","key":"3859_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10238-024-01306-2","volume":"24","author":"H Chen","year":"2024","unstructured":"Chen H, Zhao J, Zhao D, et al. Lymphoma relapse 1\u00a0year or later after immunochemotherapy in DLBCL patients: clinical features and outcome. Clin Exp Med. 2024;24(1):48. https:\/\/doi.org\/10.1007\/s10238-024-01306-2.","journal-title":"Clin Exp Med"},{"issue":"5","key":"3859_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","volume":"60","author":"SS Wang","year":"2023","unstructured":"Wang SS. Epidemiology and etiology of diffuse large B-cell lymphoma. Semin Hematol. 2023;60(5):255\u201366. https:\/\/doi.org\/10.1053\/j.seminhematol.2023.11.004.","journal-title":"Semin Hematol"},{"issue":"14","key":"3859_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2217\/fon-2018-0267","volume":"14","author":"C Casulo","year":"2018","unstructured":"Casulo C, Friedberg JW. Management of diffuse large B-cell lymphoma in elderly patients. Future Oncol. 2018;14(14):1415\u201324. https:\/\/doi.org\/10.2217\/fon-2018-0267.","journal-title":"Future Oncol"},{"issue":"13","key":"3859_CR5","doi-asserted-by":"publisher","first-page":"204062072211033","DOI":"10.1177\/20406207221103321.PMID:35785244;PMCID:PMC9243592","volume":"28","author":"F Frontzek","year":"2022","unstructured":"Frontzek F, Karsten I, Schmitz N, Lenz G. Current options and future perspectives in the treatment of patients with relapsed\/refractory diffuse large B-cell lymphoma. Ther Adv Hematol. 2022;28(13):20406207221103320. https:\/\/doi.org\/10.1177\/20406207221103321.PMID:35785244;PMCID:PMC9243592.","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"3859_CR6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ajh.24819","volume":"96","author":"MJ Maurer","year":"2021","unstructured":"Maurer MJ, et al. Comorbidities and survival in diffuse large B-cell lymphoma. Am J Hematol. 2021;96(7):846\u201354. https:\/\/doi.org\/10.1002\/ajh.24819.","journal-title":"Am J Hematol"},{"key":"3859_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. NCCN.org."},{"issue":"16","key":"3859_CR8","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2217\/fon-2023-0191","volume":"19","author":"NA Johnson","year":"2023","unstructured":"Johnson NA, LaCasce AS. Advances in the treatment of diffuse large B-cell lymphoma. Future Oncol. 2023;19(16):1167\u201377. https:\/\/doi.org\/10.2217\/fon-2023-0191.","journal-title":"Future Oncol"},{"issue":"6","key":"3859_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3892\/ol.2021.13196","volume":"26","author":"M Al-Hussaini","year":"2021","unstructured":"Al-Hussaini M, et al. The role of age and comorbidities in lymphoma outcomes. Oncol Lett. 2021;26(6):817. https:\/\/doi.org\/10.3892\/ol.2021.13196.","journal-title":"Oncol Lett"},{"issue":"26","key":"3859_CR10","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1200\/JCO.18.02079","volume":"37","author":"LJ Nastoupil","year":"2019","unstructured":"Nastoupil LJ, et al. Axicabtagene ciloleucel for relapsed\/refractory large b-cell lymphoma: real-world evidence. J Clin Oncol. 2019;37(26):2118\u201327. https:\/\/doi.org\/10.1200\/JCO.18.02079.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3859_CR11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/leu.2014.68","volume":"28","author":"CR Flowers","year":"2014","unstructured":"Flowers CR, et al. A new prognostic index for diffuse large b-cell lymphoma. Leukemia. 2014;28(6):1356\u201363. https:\/\/doi.org\/10.1038\/leu.2014.68.","journal-title":"Leukemia"},{"issue":"6","key":"3859_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2217\/fon-2023-0191","volume":"20","author":"M Garg","year":"2023","unstructured":"Garg M, Puckett J, Kamal-Bahl S, Raut M, Ryland KE, Doshi JA, Huntington SF. Real-world treatment patterns, survival, health resource use and costs among medicare beneficiaries with diffuse large B-cell lymphoma. Future Oncol. 2023;20(6):317\u201328.","journal-title":"Future Oncol"},{"issue":"23","key":"3859_CR13","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","volume":"123","author":"L Tao","year":"2014","unstructured":"Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood. 2014;123(23):3553\u201362. https:\/\/doi.org\/10.1182\/blood-2013-07-517110.","journal-title":"Blood"},{"key":"3859_CR14","unstructured":"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC2951853\/"},{"key":"3859_CR15","first-page":"CD013365","volume":"13","author":"M Ernst","year":"2021","unstructured":"Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021;13:CD013365.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3859_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/08998280.2023.2267921","volume":"37","author":"ZH Bodla","year":"2023","unstructured":"Bodla ZH, Hashmi M, Niaz F, et al. Independent predictors of mortality and 5-year trends in mortality and resource utilization in hospitalized patients with diffuse large B cell lymphoma. Proc (Bayl Univ Med Cent). 2023;37(1):16\u201324. https:\/\/doi.org\/10.1080\/08998280.2023.2267921.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"3859_CR17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England J Med. 2022;386:620\u201354.","journal-title":"New England J Med"},{"issue":"6","key":"3859_CR18","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/14737167.2019.168028","volume":"19","author":"RA Harkins","year":"2019","unstructured":"Harkins RA, Patel SP, Flowers CR. Cost burden of diffuse large B-cell lymphoma. Expert Rev Pharmacoecon Outcomes Res. 2019;19(6):645\u201361. https:\/\/doi.org\/10.1080\/14737167.2019.168028.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3859_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F. Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma. New England J Med. 2022;386:351\u201362.","journal-title":"New England J Med"},{"issue":"1","key":"3859_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1080\/13696998.2023.2254640","volume":"26","author":"M Matasar","year":"2023","unstructured":"Matasar M, Masaquel A, Ho S, et al. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. J Med Econ. 2023;26(1):1134\u201344. https:\/\/doi.org\/10.1080\/13696998.2023.2254640.","journal-title":"J Med Econ"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-03859-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-03859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:51:26Z","timestamp":1757137886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-03859-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["3859"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-03859-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not needed as the data have been collected from public databases.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board approval"}}]}}